# Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

> **NCT04634825** · PHASE2 · TERMINATED · sponsor: **MacroGenics** · enrollment: 62 (actual)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Neoplasms
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Enoblituzumab
- **BIOLOGICAL:** Retifanlimab
- **BIOLOGICAL:** Tebotelimab

## Key facts

- **NCT ID:** NCT04634825
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Based on internal review of safety data
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634825, "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04634825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*